Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: Rationale, Design, and Lead-in Phase Results of the REBALANCE-HF Trial

Splanchnic vasoconstriction augments transfer of blood volume from the abdomen into the thorax, which may increase filling pressures and hemodynamic congestion in patients with noncompliant hearts. Therapeutic interruption of splanchnic nerve activity holds promise to reduce hemodynamic congestion in patients with heart failure with preserved ejection fraction (HFpEF). Here we describe (1) the rationale and design of the first sham-controlled randomized clinical trial (RCT) of splanchnic nerve ablation for HFpEF; and (2) the 12-month results of the lead-in (open-label) trial participants.

Source: Journal of Cardiac Failure - January 9, 2024 Category: Cardiology Authors: Marat Fudim, Sheldon Litwin, Barry A. Borlaug, Rajeev C. Mohan, Matthew J. Price, Peter Fail, Teona Zirakashvili, Tamaz Shaburishvili, Parag Goyal, Scott L. Hummel, Ravi B. Patel, Vivek Y. Reddy, Daniel Burkhoff, Manesh R. Patel, Sami I. Somo, Sanjiv J. S Source Type: research